DEFUSE 3: Collateral Status Not Associated With Outcomes in Stroke Patients Treated in Late Therapeutic Window
The “collateral story” may be more complicated than previously thought, highlighting the need for more research into their evolution and role.
The most inclusive criteria from both trials should be adopted, experts conclude.…
The randomized trial is on schedule, while the registry is training a generation of operators, CREST-2 investigators said at ISET 2018.
Beyond the big trials, presentations at this year’s International Stroke Conference point to a maturing field that’s under active study.
About two-thirds of operators over a recent 7-year period had completed a neurointerventional fellowship.
The DAWN and DEFUSE 3 trials show that perfusion imaging can identify patients who benefit 6 to 24 hours after stroke onset.
Case Upload for Simulation
Case submissionSEE AN EXAMPLE NOW
Submit your case to obtain a personalized predictive simulation of braided stents in the treatment of intracranial aneurysms for precise and safe implantation. This service is supported by Neurovascular Exchange and ANKYRAS.